fda tirzepatide news Grants a New Indication for Obesity Management FDA approval for Zepbound: FSU

Schedule a consultation with us today to explore our range of personalized programs, designed to support your health goals and enhance your quality of life

Administration and dosing Tirzepatide is administered as a once-weekly subcutaneous injection using an auto-injector pen

Structural formula: MOUNJARO is a clear, colorless to slightly yellow, sterile solution for subcutaneous use

Figure 6: Change in Body Weight (%) After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight Note: Displayed results are from the randomized population

The cautionary note in the tirzepatide study is worthy of consideration